{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-039945","form_type":"8-K","ticker":"IDXG","cik":"0001054102","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.055252+00:00","generated_at":"2026-06-08T08:34:39.171127+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Interpace Biosciences Q3 revenue $9.1M (+11% YoY); expects FY2023 revenue >$40M","bullets":["Q3 net revenue $9.1M, up 11% from $8.2M; test volume up 11% YoY.","Loss from continuing ops $(0.5)M vs $(1.3)M; adjusted EBITDA $0.4M vs $0.1M.","Repaid $2.5M Comerica line of credit and $3M Terminal Payment to BroadOak; renegotiated long-term debt.","Cash balance $5.0M at Sept 30, 2023; cash collections $9.8M vs $7.6M.","Expects full-year 2023 revenue to exceed $40M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-039945","json":"https://secwatch.observer/filing/0001493152-23-039945.json","markdown":"https://secwatch.observer/filing/0001493152-23-039945.md","text":"https://secwatch.observer/filing/0001493152-23-039945.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1054102/000149315223039945/0001493152-23-039945-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1054102/000149315223039945/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T08:34:39.171127+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6bb34ec7067c24d7238fd54e34118f0fbf8713a6","claim":"INTERPACE BIOSCIENCES, INC. reported nine months ended September 30, 2023 results: revenue $29.9 million. Guidance reaffirmed.","evidence_excerpt":"For the Nine Months Ended September 30, 2023 as Compared to the Nine Months Ended September 30, 2022 ● Net Revenue was $29.9 million, an increase of 27% from $23.5 million for the prior year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315223039945/0001493152-23-039945-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"nine months ended September 30, 2023"},{"label":"Revenue","value":"$29.9 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"d21a06da48ad70c8656139b96416060140e29e85","claim":"INTERPACE BIOSCIENCES, INC. reported third quarter ended September 30, 2023 results: revenue $9.1 million. Guidance reaffirmed.","evidence_excerpt":"in such filing. --- EX-99.1 () --- EX-99.1 2 ex99-1.htm Exhibit 99.1 Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results ● Q3 Revenue of $9.1 million; an 11% increase year-over-year ● Q3 Test volume up 11% year-over-year ● Q3 Reimbursement improvement up 11% year-over-year, driven by additional commercial contracts and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315223039945/0001493152-23-039945-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$9.1 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}